Commercial Division Dismisses Securities Class Action Against Pharmaceutical Company Alleging Failure to Disclose Results from Phase 3 Clinical Trial | Patterson Belknap Webb & Tyler LLP

One of the most significant pieces of legislation to emerge from the New Deal, the Securities Act 1933 (“the 1933 Act”), imposes a disclosure requirement for registration statements and...

Related Keywords

New York ,United States ,Blackrock ,Massachusetts , ,Omnicare Inc ,York Supreme Court ,Keryx Biopharmaceuticals Inc ,Council Const ,Drug Administration ,Avon Prods Inc ,Blackrock Inc ,Division Decision ,Akebia Therapeutics Inc ,Patterson Belknap Webb Tyler ,Patterson Belknap Webb ,New Deal ,Securities Act ,Commercial Division ,Akebia Therapeutics ,Keryx Biopharmaceuticals ,New York Supreme Court ,New York Based ,